

Amir M Sherif

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4155634/amir-m-sherif-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

76
papers

2,852
citations

22
h-index

53
g-index

83
ext. papers

3,441
ext. citations

4.5
avg, IF

4.64
L-index

#	Paper	IF	Citations
76	Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma.. <i>Scandinavian Journal of Urology</i> , 2022 , 1-10	1.6	1
75	Standardized care pathways for patients with suspected urinary bladder cancer: the Swedish experience.. <i>Scandinavian Journal of Urology</i> , 2022 , 1-6	1.6	1
74	A prospective multicenter study of visual response-evaluation by cystoscopy in patients undergoing neoadjuvant chemotherapy for muscle invasive urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021 , 1-7	1.6	1
73	Risk of bladder cancer death in patients younger than 50 with non-muscle-invasive and muscle-invasive bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021 , 1-7	1.6	1
72	Bladder cancer recurrence in papillary urothelial neoplasm of low malignant potential (PUNLMP) compared to G1 WHO 1999: a population-based study. <i>Scandinavian Journal of Urology</i> , 2021 , 1-5	1.6	0
71	A population-based study on the effect of a routine second-look resection on survival in primary stage T1 bladder cancer. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 108-115	1.6	0
70	Thromboembolism in Muscle-Invasive Bladder Cancer. A Population-based Nationwide Study. <i>Bladder Cancer</i> , 2021 , 7, 161-171	1	1
69	Survival after radical cystectomy during holiday periods. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 276-280		2
68	Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour. <i>Cancers</i> , 2021 , 13,	6.6	2
67	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	9
66	Cumulative incidence of midline incisional hernia and its surgical treatment after radical cystectomy and urinary diversion for bladder cancer: A nation-wide population-based study. <i>PLoS ONE</i> , 2021 , 16, e0246703	3.7	2
65	Cumulative incidence of ureteroenteric strictures after radical cystectomy in a population-based Swedish cohort. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 361-365	1.6	0
64	Control computerized tomography in neoadjuvant chemotherapy for muscle invasive urinary bladder cancer has no value for treatment decisions and low correlation with nodal status. <i>Scandinavian Journal of Urology</i> , 2021 , 55, 455-460	1.6	1
63	Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer. <i>Investigative and Clinical Urology</i> , 2021 , 62, 39-46	1.9	
62	Urinary Exosomes from Bladder Cancer Patients Show a Residual Cancer Phenotype despite Complete Pathological Downstaging. <i>Scientific Reports</i> , 2020 , 10, 5960	4.9	16
61	Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival. <i>Scandinavian Journal of Urology</i> , 2020 , 54, 46-51	1.6	2
60	Sustainable long-term results on postoperative sexual activity after radical prostatectomy when a clinical sexologist is included in the sexual rehabilitation process. A retrospective study on 7 years postoperative outcome. <i>Central European Journal of Urology</i> , 2020 , 73, 551-557	0.9	1

59	Tumour-associated B cells in urothelial urinary bladder cancer. <i>Scandinavian Journal of Immunology</i> , 2020 , 91, e12830	3.4	12
58	The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation. <i>International Urology and Nephrology</i> , 2020 , 52, 661-669	2.3	3
57	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
56	Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. <i>World Journal of Urology</i> , 2020 , 38, 2207-2213	4	2
55	Treatment and prognosis of patients with urinary bladder cancer with other primary cancers: a nationwide population-based study in the Bladder Cancer Data Base Sweden (BladderBaSe). <i>BJU International</i> , 2020 , 126, 625-632	5.6	2
54	Computerized tomography before the final treatment cycle of neoadjuvant chemotherapy or induction chemotherapy in muscle-invasive urinary bladder cancer, cannot predict pathoanatomical outcomes and does not reflect prognosis-results of a single centre retrospective prognostic study. <i>Translational Urology and Urology</i> , 2020 , 9, 1010-1018	2.3	1
53	IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity. <i>Scandinavian Journal of Immunology</i> , 2020 , 92, e12926	3.4	2
52	No increased risk of short-term complications after radical cystectomy for muscle-invasive bladder cancer among patients treated with preoperative chemotherapy: a nation-wide register-based study. <i>World Journal of Urology</i> , 2020 , 38, 381-388	4	9
51	Management and outcome of TaG3 tumours of the urinary bladder in the nationwide, population-based bladder cancer database Sweden (BladderBaSe). <i>Scandinavian Journal of Urology</i> , 2019 , 53, 200-205	1.6	
50	Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival. <i>Scandinavian Journal of Urology</i> , 2019 , 53, 206-212	1.6	4
49	Period-specific mean annual hospital volume of radical cystectomy is associated with outcome and perioperative quality of care: a nationwide population-based study. <i>BJU International</i> , 2019 , 124, 449-456	5.6	7
48	Incidence, survival and mortality trends of bladder cancer in Sweden 1997-2016. <i>Scandinavian Journal of Urology</i> , 2019 , 53, 193-199	1.6	9
47	Management and outcome of muscle-invasive bladder cancer with clinical lymph node metastases. A nationwide population-based study in the bladder cancer data base Sweden (BladderBaSe). <i>Scandinavian Journal of Urology</i> , 2019 , 53, 332-338	1.6	3
46	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019 , 30, 1697-1727	10.3	28
45	Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 186-193	1.6	7
44	Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness. <i>Cancer Immunology Research</i> , 2018 , 6, 528-538	12.5	25
43	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018 , 4, 1-7	1	4
42	Increased CD4 T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. <i>Clinical Epigenetics</i> , 2018 , 10, 102	7.7	14

41	Tissue-resident memory T cells are epigenetically cytotoxic with signs of exhaustion in human urinary bladder cancer. <i>Clinical and Experimental Immunology</i> , 2018 , 194, 39-53	6.2	30
40	Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. <i>European Urology</i> , 2018 , 74, 688-692	10.2	19
39	Detection of micro-metastases by flow cytometry in lymph nodes from patients with penile cancer. <i>BMC Urology</i> , 2018 , 18, 86	2.2	1
38	Urothelial bladder cancer may suppress perforin expression in CD8+ T cells by an ICAM-1/TGFβ mediated pathway. <i>PLoS ONE</i> , 2018 , 13, e0200079	3.7	11
37	Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer. <i>Clinical Immunology</i> , 2017 , 176, 63-70	9	19
36	Evaluation of the diagnostic accuracy of UBC Rapid in bladder cancer: a Swedish multicentre study. <i>Scandinavian Journal of Urology</i> , 2017 , 51, 293-300	1.6	13
35	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017 , 72, 509-518	10.2	14
34	Cohort profile: The Swedish National Register of Urinary Bladder Cancer (SNRUBC) and the Bladder Cancer Data Base Sweden (BladderBaSe). <i>BMJ Open</i> , 2017 , 7, e016606	3	30
33	Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report. <i>World Journal of Urology</i> , 2017 , 35, 921-927	4.27	10
32	A retrospective evaluation of preoperative anemia in patients undergoing radical cystectomy for muscle-invasive urothelial urinary bladder cancer, with or without neoadjuvant chemotherapy. <i>SpringerPlus</i> , 2016 , 5, 1167		7
31	Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival. <i>BJU International</i> , 2016 , 117, 287-92	5.6	52
30	Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours. <i>British Journal of Cancer</i> , 2016 , 115, 957-966	8.7	17
29	Pilot study of adoptive immunotherapy with sentinel node-derived T cells in muscle-invasive urinary bladder cancer. <i>Scandinavian Journal of Urology</i> , 2015 , 49, 453-462	1.6	10
28	B cells in tumor draining lymph nodes act as efficient antigen presenting cells in cancer patients 2015 , 3,		78
27	EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. <i>European Urology</i> , 2014 , 65, 778-92	10.2	727
26	The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review. <i>European Urology</i> , 2014 , 66, 1065-77	10.2	118
25	Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1215-24	2.8	7
24	Multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies. <i>Journal of Immunology</i> , 2013 , 190, 5847-55	5.3	42

23	The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. <i>Clinical and Experimental Immunology</i> , 2013 , 172, 490-9	6.2	36
22	The many flavors of tumor-associated B cells. <i>Oncolmmunology</i> , 2013 , 2, e25237	7.2	4
21	Response to comment on "multiplex B cell characterization in blood, lymph nodes, and tumors from patients with malignancies". <i>Journal of Immunology</i> , 2013 , 191, 4471-2	5.3	1
20	Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. <i>European Urology</i> , 2012 , 61, 1229-38	10.2	166
19	Sentinel node detection in renal cell carcinoma. A feasibility study for detection of tumour-draining lymph nodes. <i>BJU International</i> , 2012 , 109, 1134-9	5.6	22
18	FOXP3 and survival in urinary bladder cancer. <i>BJU International</i> , 2011 , 108, 1672-8	5.6	102
17	Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. <i>European Urology</i> , 2011 , 59, 1009-18	10.2	465
16	Neoadjuvant Chemotherapy 2011 , 377-386		
15	Feasibility of T-cell-based adoptive immunotherapy in the first 12 patients with advanced urothelial urinary bladder cancer. Preliminary data on a new immunologic treatment based on the sentinel node concept. <i>European Urology</i> , 2010 , 58, 105-11	10.2	24
14	Current status of prognostic immunohistochemical markers for urothelial bladder cancer. <i>Tumor Biology</i> , 2008 , 29, 311-22	2.9	22
13	Treatment of muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2007 , 7, 1279-83	3.5	20
12	Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2007 , 33, 840-1	2	
11	Detection of immune responses against urinary bladder cancer in sentinel lymph nodes. <i>European Urology</i> , 2006 , 49, 59-70	10.2	34
10	Hybrid SPECT-CT: an additional technique for sentinel node detection of patients with invasive bladder cancer. <i>European Urology</i> , 2006 , 50, 83-91	10.2	62
9	Neoadjuvant cisplatin based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. <i>European Urology</i> , 2004 , 45, 297-303	10.2	170
8	Re: extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. <i>Journal of Urology</i> , 2004 , 172, 386; author reply 386	2.5	2
7	Early Metastatic Progression of Bladder Carcinoma: Molecular Profile of Primary Tumor and Sentinel Lymph Node. <i>Journal of Urology</i> , 2002 , 168, 2240-2244	2.5	23
6	Endovascular approach to treating secondary arterioureteral fistula. <i>Scandinavian Journal of Urology and Nephrology</i> , 2002 , 36, 80-2		17

5	Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. <i>Scandinavian Journal of Urology and Nephrology</i> , 2002 , 36, 419-25		130
4	Early metastatic progression of bladder carcinoma: molecular profile of primary tumor and sentinel lymph node. <i>Journal of Urology</i> , 2002 , 168, 2240-4	2.5	7
3	LYMPHATIC MAPPING AND DETECTION OF SENTINEL NODES IN PATIENTS WITH BLADDER CANCER. <i>Journal of Urology</i> , 2001 , 166, 812-815	2.5	80
2	Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer. <i>Journal of Urology</i> , 2001 , 166, 812-5	2.5	17
1	Thromboembolic events during neoadjuvant chemotherapy in muscle invasive bladder cancer: any correlation to the central venous access? A clinical practice article. <i>F1000Research</i> , 11, 40	3.6	